Compare NEO & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEO | BCX |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 949.9M |
| IPO Year | 2008 | N/A |
| Metric | NEO | BCX |
|---|---|---|
| Price | $9.18 | $12.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $13.38 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 179.8K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.99% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.63 | N/A |
| Revenue Next Year | $9.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $9.23 |
| 52 Week High | $13.74 | $13.86 |
| Indicator | NEO | BCX |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 43.06 |
| Support Level | $7.42 | $11.91 |
| Resistance Level | $10.82 | $12.58 |
| Average True Range (ATR) | 0.40 | 0.19 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 84.81 | 16.44 |
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies, or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.